ARTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Artiva Biotherapeutics Inc (ARTV) is not a strong buy at the moment for a beginner, long-term investor. While the stock has shown significant recent gains, the overbought RSI and lack of positive financial performance or news catalysts suggest caution. The absence of trading signals and weak financials further support a hold recommendation.
The MACD is positive and expanding, indicating bullish momentum. The RSI is at 92.733, signaling an overbought condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key resistance levels are R1: 11.135 and R2: 12.634, with the current price near these levels, suggesting limited upside in the short term.
The stock has shown a 33.08% regular market gain, and the MACD indicates bullish momentum.
The RSI indicates the stock is overbought, and the financial performance remains weak with no revenue growth and negative net income. No recent news or significant trading trends from insiders or hedge funds. Congress trading data is also absent.
In Q4 2025, revenue was $0 with no YoY growth. Net income improved by 29.06% YoY but remains negative at -$20.77M. EPS increased by 28.79% YoY to -0.85. Gross margin dropped to 0, down 100% YoY, indicating poor financial health.
No analyst rating or price target changes available.
